Hard NAPLEX Bioavailability Practice Questions

Mastering Hard NAPLEX Bioavailability calculations is essential for ensuring patient safety and therapeutic efficacy when transitioning medications between different routes of administration. Bioavailability ($F$) represents the fraction of an administered dose that reaches the systemic circulation in an unchanged form. While intravenous (IV) administration is defined by a bioavailability of 1 (100%), extravascular routes such as oral, subcutaneous, or rectal administration often result in $F < 1$ due to incomplete absorption or first-pass metabolism in the liver. Understanding these principles is a foundational part of NAPLEX Prep, as pharmacists must frequently calculate equivalent doses when patients transition from hospital-based IV therapy to outpatient oral regimens.

Concept Explanation

Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. In clinical practice, we primarily focus on absolute bioavailability, which compares the bioavailability of the active drug in the systemic circulation following extravascular administration with the bioavailability of the same drug following intravenous administration. This is mathematically expressed using the Area Under the Curve (AUC) from plasma concentration-time profiles.

The formula for absolute bioavailability ($F$) is:

$$F = \frac{[AUC]_{oral} \times Dose_{IV}}{[AUC]_{IV} \times Dose_{oral}}$$

When switching a patient from one dosage form to another, the pharmacist must ensure the systemic exposure remains consistent. The equivalent dose can be calculated using the following relationship:

$$Dose_{new} = \frac{Dose_{current} \times F_{current}}{F_{new}}$$

Several factors influence bioavailability, including the drug's physiochemical properties (solubility and permeability), the formulation (extended-release vs. immediate-release), and physiological factors like gastric emptying time or the presence of liver disease which can significantly alter first-pass metabolism. For drugs with high first-pass metabolism, the oral dose will be substantially higher than the IV dose to achieve the same therapeutic effect.

Solved Examples

1. Calculating Absolute Bioavailability: A new antifungal drug was administered to a volunteer. A 100 mg IV dose resulted in an AUC of 50 mg*hr/L. A 200 mg oral dose resulted in an AUC of 60 mg*hr/L. Calculate the absolute bioavailability ($F$) of the oral formulation.
   1. Identify the variables: $Dose_{IV} = 100$, $AUC_{IV} = 50$, $Dose_{oral} = 200$, $AUC_{oral} = 60$.
   2. Apply the formula: $F = \frac{60 \times 100}{50 \times 200}$.
   3. Calculate: $F = \frac{6000}{10000} = 0.6$.
   4. The absolute bioavailability is 60%.
2. IV to PO Conversion: A patient is receiving IV Ciprofloxacin 400 mg every 12 hours. The oral bioavailability of Ciprofloxacin is 70%. What is the equivalent oral dose ($mg$) if the physician wants to maintain the same systemic exposure?
   1. Identify the daily IV dose: $400 \text{ mg} \times 2 = 800 \text{ mg/day}$.
   2. Recognize $F_{IV} = 1$ and $F_{PO} = 0.7$.
   3. Apply the conversion formula: $Dose_{PO} = \frac{800 \text{ mg} \times 1}{0.7}$.
   4. Calculate: $800 / 0.7 = 1142.8 \text{ mg}$.
   5. Rounding to the nearest standard tablet size (500 mg or 750 mg), the pharmacist would likely recommend 500 mg PO BID or 750 mg PO BID depending on clinical severity. For the calculation, the exact answer is 1142.9 mg.
3. Salt Factor Consideration: A patient is taking 300 mg of Phenytoin sodium (S = 0.92) capsules daily. The physician wants to switch the patient to Phenytoin suspension (S = 1.0). What is the equivalent dose of the suspension?
   1. Calculate the amount of active phenytoin in the capsules: $300 \text{ mg} \times 0.92 = 276 \text{ mg}$.
   2. Since the suspension has a salt factor of 1.0, the dose of the suspension must provide 276 mg of active drug.
   3. $Dose_{suspension} = \frac{276 \text{ mg}}{1.0} = 276 \text{ mg}$.

Practice Questions

1. A drug has an oral bioavailability of 25%. If the standard IV dose is 50 mg every 8 hours, what is the total daily oral dose required to provide equivalent exposure? (Round to the nearest whole number).

2. A pharmaceutical company is testing a new tablet. The AUC for a 500 mg dose of the tablet is 120 mg*hr/L. The AUC for a 250 mg IV bolus of the same drug is 150 mg*hr/L. Calculate the absolute bioavailability of the tablet as a percentage.

3. Patient KT is being discharged on oral levofloxacin. In the hospital, KT received 750 mg IV daily. Levofloxacin has an oral bioavailability of 99%. What is the equivalent oral daily dose? (Round to the nearest whole number).

4. A patient is currently taking 0.25 mg of Digoxin tablets ($F = 0.7$) daily. The pharmacy is out of tablets and only has Digoxin elixir ($F = 0.8$) available. What volume of the 0.05 mg/mL elixir should the patient receive to maintain the same dose? (Round to the nearest mL).

5. Aminophylline is 80% theophylline. If a patient is taking 400 mg of Theo-24 (theophylline) capsules daily, what is the equivalent dose of IV aminophylline required per day? (Round to the nearest whole number).

6. A drug follows first-order kinetics. A 100 mg IV dose produces an AUC of 45 mg*hr/L. A 500 mg oral dose produces an AUC of 90 mg*hr/L. What is the fraction of the drug that is absorbed ($F$)?

7. A patient with renal impairment requires a dose adjustment for a drug with 60% oral bioavailability. If the adjusted IV dose is 120 mg BID, what is the equivalent oral dose for a once-daily regimen? (Round to the nearest whole number).

8. Calculate the bioavailability of a drug if the oral AUC is 180 \u03bcg*hr/mL after a 400 mg dose and the IV AUC is 240 \u03bcg*hr/mL after a 200 mg dose. Express as a percentage.

9. A patient is switching from Morphine IV to Morphine PO. The patient has been receiving 2 mg/hr IV Morphine. The IV:PO ratio for morphine is 1:3. What is the total daily oral dose of morphine required? (Round to the nearest whole number).

10. A drug has a salt factor ($S$) of 0.75 and a bioavailability ($F$) of 0.6. If a patient needs 300 mg of the active drug systemically, what oral dose of the salt form should be administered? (Round to the nearest whole number).

Answers & Explanations

1. 600 mg: The daily IV dose is $50 \text{ mg} \times 3 = 150 \text{ mg}$. Using $Dose_{PO} = Dose_{IV} / F$, we get $150 / 0.25 = 600 \text{ mg}$.
2. 40%: $F = \frac{120 \times 250}{150 \times 500} = \frac{30000}{75000} = 0.4$. As a percentage, this is 40%.
3. 758 mg: $Dose_{PO} = 750 / 0.99 = 757.57$. Rounded to the nearest whole number, it is 758 mg. In clinical practice, 750 mg is used due to high bioavailability.
4. 4 mL: First, find the amount of active drug needed: $0.25 \text{ mg} \times 0.7 = 0.175 \text{ mg}$. Now, find the dose of elixir: $0.175 / 0.8 = 0.21875 \text{ mg}$. Volume = $0.21875 \text{ mg} / 0.05 \text{ mg/mL} = 4.375 \text{ mL}$. Rounded to the nearest mL, it is 4 mL.
5. 500 mg: The patient needs 400 mg of theophylline. Since aminophylline is only 80% theophylline ($S = 0.8$), the dose is $400 / 0.8 = 500 \text{ mg}$.
6. 0.4: $F = \frac{90 \times 100}{45 \times 500} = \frac{9000}{22500} = 0.4$.
7. 400 mg: Total daily IV dose = $120 \text{ mg} \times 2 = 240 \text{ mg}$. Oral dose = $240 / 0.6 = 400 \text{ mg}$ once daily.
8. 37.5%: $F = \frac{180 \times 200}{240 \times 400} = \frac{36000}{96000} = 0.375$, which is 37.5%.
9. 144 mg: Total daily IV morphine = $2 \text{ mg/hr} \times 24 \text{ hours} = 48 \text{ mg}$. Using the 1:3 ratio, the oral dose is $48 \times 3 = 144 \text{ mg}$.
10. 667 mg: The amount that reaches circulation is $Dose \times S \times F$. Therefore, $300 = Dose \times 0.75 \times 0.6$. $300 = Dose \times 0.45$. $Dose = 300 / 0.45 = 666.67 \text{ mg}$. Rounded to 667 mg.

1. Which of the following defines absolute bioavailability?

• AThe ratio of AUC of two different oral formulations.
• BThe ratio of AUC of an oral dose compared to an IV dose.
• CThe time it takes for the drug to reach peak concentration.
• DThe total volume of distribution divided by the dose.

Frequently Asked Questions

What is the difference between absolute and relative bioavailability?

Absolute bioavailability compares the bioavailability of a non-intravenous dose to an intravenous dose, whereas relative bioavailability compares the bioavailability of two different formulations (e.g., tablet vs. capsule) of the same drug given by the same non-IV route. Absolute bioavailability uses IV as the 100% reference point, while relative bioavailability compares one product to a standard reference product.

How does the first-pass effect impact bioavailability?

The first-pass effect occurs when a drug is metabolized by the liver or gut wall before it reaches the systemic circulation, significantly reducing the amount of active drug available. High first-pass metabolism results in low oral bioavailability, often requiring much larger oral doses compared to intravenous doses to achieve therapeutic levels.

What is the "Salt Factor" (S) in bioavailability calculations?

The salt factor, or S-value, represents the fraction of the drug formulation that is the active drug moiety rather than the salt, ester, or conjugate. For example, if a drug is administered as a salt with an S-value of 0.8, only 80% of the weight of the administered dose is the actual active medication.

Why is AUC used to measure bioavailability?

The Area Under the Curve (AUC) is a pharmacokinetic parameter that represents the total drug exposure over time in the systemic circulation. By comparing the AUC of an extravascular dose to the AUC of an IV dose (corrected for dose amount), clinicians can determine exactly what fraction of the drug was absorbed into the blood.

Which drugs typically have 1:1 IV to PO conversion?

Drugs with very high oral bioavailability, such as Levofloxacin, Linezolid, and Fluconazole, typically have a 1:1 IV to PO conversion ratio. For these medications, the oral absorption is so efficient (often >90%) that the dose remains the same regardless of whether it is given intravenously or orally.